单硝酸异山梨酯注射液辅助治疗对冠心病SAP患者的影响

Effect of Isosorbide Mononitrate Injection Adjuvant Therapyon Stable Angina Pectoris with Coronary Heart Disease

目的研究单硝酸异山梨酯注射液联合地尔硫卓片对冠心病稳定型心绞痛(stable angina pectoris,SAP)患者症状改善及心电图变化的影响。方法以2019年10月~2022年12月在某院收治的106例冠心病SAP患者为研究对象,采用随机数字表法分为对照组(53例)、联合组(53例)。对照组采用地尔硫卓片治疗,联合组采用注射用单硝酸异山梨酯注射液联合地尔硫卓片治疗。比较2组临床疗效、治疗前及治疗2周后症状改善情况、心电图变化情况、血清超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)、C1q/TNF相关蛋白3(CTRP3)、C1q/TNF相关蛋白9(CTRP9)水平、不良反应发生率。结果联合组临床总有效率(94.30%)高于对照组(81.13%,P<0.05);治疗2周后,联合组心绞痛发作次数、心绞痛持续时间低于对照组(P<0.05);治疗2周后,联合组ST段压低次数、ST段压低幅度、T波下降幅度低于对照组(P<0.05);治疗2周后,联合组血清hs-CRP、Hcy水平低于对照组,CTRP3、CTRP9水平高于对照组(P<0.05);联合组不良反应总发生率(9.43%)与对照组(5.66%)相比,差异无统计学意义(P>0.05)。结论采用注射用单硝酸异山梨酯注射液联合地尔硫卓片治疗冠心病SAP可提高临床疗效,显著缓解症状,改善心电图,抑制炎症反应,且具有一定安全性。

OBJECTIVE To study the effect of isosorbide mononitrate injection combined with diltiazem tablets on symptom improvement and ECG changes in patients with stable angina pectoris(SAP)of coronary heart disease.METHODS A total of 106patients with SAP of coronary heart disease admitted to ahospital from October 2019 to December 2022 were divided into control group(53 cases)and combined group(53 cases)by random number table method.The control group was treated with diltiazem tablets,and the combination group was treated with isosorbide mononitrate injection combined with diltiazem tablets.The clinical efficacy,symptom improvement before and after treatment and 2 weeks after treatment were compared,ECG changes,serum hypersensitivity C-reactive protein(hs-CRP),homocysteine(Hcy),C1q/TNF-associated protein 3(CTRP3),C1q/TNF-related protein 9(CTRP9)levels,and the incidence of adverse reactions were compared between the two groups.RESULTS The total clinical effective rate of the combined group(94.30%)was higher than that of the control group(81.13%)(P<0.05).After 2 weeks of treatment,the number of angina attacks and the duration of angina in the combined group were lower than those of the control group(P<0.05).and the number of ST segment depression,ST segment depression amplitude and T wave decrease amplitude of the combination group were lower than that of the control group(P<0.05),the serum hs-CRP and Hcy levels of the combined group were lower than those in the control group.The level of CTRP3 and CTRP9 were higher than that in the control group(P<0.05),and the total incidence of adverse reactions in the combination group(9.43%)was not significantly different from that in the control group(5.66%)(P>0.05).CONCLUSION The use of isosorbide mononitrate injection combined with diltiazem tablets for the treatment of coronary heart disease SAP can improve clinical efficacy,significantly relieve symptoms,improve electrocardiogram,inhibit inflammatory response,and have a certain safety.